Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
C. Zhou(Tongji University), Yi‐Long Wu(Guangdong General Hospital), G. Chen(Harbin Medical University), J. Feng(Jiangsu Cancer Hospital), Xuetong Liu(Academy of Military Medical Sciences), C. Wang(Tianjin Medical University Cancer Institute and Hospital), S. Zhang(Capital Medical University), J. Wang(Peking University), Songwen Zhou(Tongji University), Shengxiang Ren(Tongji University), Shun Lü(Shanghai Jiao Tong University), L. Zhang(Sun Yat-sen University), Chengping Hu(Central South University), Chengping Hu(Central South University), Yi Luo(Hunan Cancer Hospital), Lin Chen(Shantou University), M. Ye(Shanghai Jiao Tong University), Juanjuan Huang(Soochow University), X. Zhi(Capital Medical University), Y. Zhang(Zhejiang Cancer Hospital), Qingyu Xiu(Second Military Medical University), W. F. Mader(Harbin Institute of Petroleum), L. Zhang(Sun Yat-sen University), Changxuan You(Nanfang Hospital)
Cited by 465
Abstract
Related Papers
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay, Isabelle Soerjomataram, Rajesh Dikshit et al.|International Journal of Cancer|2014|29k